319 related articles for article (PubMed ID: 32528479)
21. Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
Marsh S; Hanson B; Wood MJA; Varela MA; Roberts TC
Mol Ther; 2020 Dec; 28(12):2527-2539. PubMed ID: 33171139
[TBL] [Abstract][Full Text] [Related]
22. Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements.
Lattanzi A; Meneghini V; Pavani G; Amor F; Ramadier S; Felix T; Antoniani C; Masson C; Alibeu O; Lee C; Porteus MH; Bao G; Amendola M; Mavilio F; Miccio A
Mol Ther; 2019 Jan; 27(1):137-150. PubMed ID: 30424953
[TBL] [Abstract][Full Text] [Related]
23. Refined sgRNA efficacy prediction improves large- and small-scale CRISPR-Cas9 applications.
Labuhn M; Adams FF; Ng M; Knoess S; Schambach A; Charpentier EM; Schwarzer A; Mateo JL; Klusmann JH; Heckl D
Nucleic Acids Res; 2018 Feb; 46(3):1375-1385. PubMed ID: 29267886
[TBL] [Abstract][Full Text] [Related]
24. CRISPR/Cas9-Mediated Genome Editing in Epstein-Barr Virus-Transformed Lymphoblastoid B-Cell Lines.
Jiang S; Wang LW; Walsh MJ; Trudeau SJ; Gerdt C; Zhao B; Gewurz BE
Curr Protoc Mol Biol; 2018 Jan; 121():31.12.1-31.12.23. PubMed ID: 29337376
[TBL] [Abstract][Full Text] [Related]
25. Genome editing using CRISPR/Cas9-based knock-in approaches in zebrafish.
Albadri S; Del Bene F; Revenu C
Methods; 2017 May; 121-122():77-85. PubMed ID: 28300641
[TBL] [Abstract][Full Text] [Related]
26. Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins.
Naeimi Kararoudi M; Dolatshad H; Trikha P; Hussain SA; Elmas E; Foltz JA; Moseman JE; Thakkar A; Nakkula RJ; Lamb M; Chakravarti N; McLaughlin KJ; Lee DA
J Vis Exp; 2018 Jun; (136):. PubMed ID: 29985369
[TBL] [Abstract][Full Text] [Related]
27. Engineered miniature CRISPR-Cas system for mammalian genome regulation and editing.
Xu X; Chemparathy A; Zeng L; Kempton HR; Shang S; Nakamura M; Qi LS
Mol Cell; 2021 Oct; 81(20):4333-4345.e4. PubMed ID: 34480847
[TBL] [Abstract][Full Text] [Related]
28. Sequential Activation of Guide RNAs to Enable Successive CRISPR-Cas9 Activities.
Clarke R; Terry AR; Pennington H; Hasty C; MacDougall MS; Regan M; Merrill BJ
Mol Cell; 2021 Jan; 81(2):226-238.e5. PubMed ID: 33378644
[TBL] [Abstract][Full Text] [Related]
29. CRISPR-Cas9 Genome Editing in Human Cell Lines with Donor Vector Made by Gibson Assembly.
Sahoo N; Cuello V; Udawant S; Litif C; Mustard JA; Keniry M
Methods Mol Biol; 2020; 2115():365-383. PubMed ID: 32006411
[TBL] [Abstract][Full Text] [Related]
30. Dead Cas Systems: Types, Principles, and Applications.
Brezgin S; Kostyusheva A; Kostyushev D; Chulanov V
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801211
[TBL] [Abstract][Full Text] [Related]
31. Disabling Cas9 by an anti-CRISPR DNA mimic.
Shin J; Jiang F; Liu JJ; Bray NL; Rauch BJ; Baik SH; Nogales E; Bondy-Denomy J; Corn JE; Doudna JA
Sci Adv; 2017 Jul; 3(7):e1701620. PubMed ID: 28706995
[TBL] [Abstract][Full Text] [Related]
32. Precise and Predictable CRISPR Chromosomal Rearrangements Reveal Principles of Cas9-Mediated Nucleotide Insertion.
Shou J; Li J; Liu Y; Wu Q
Mol Cell; 2018 Aug; 71(4):498-509.e4. PubMed ID: 30033371
[TBL] [Abstract][Full Text] [Related]
33. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
Fujii R; Schlom J; Hodge JW
J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113
[TBL] [Abstract][Full Text] [Related]
34. Engineering NK-92 Cell by Upregulating CXCR2 and IL-2 Via CRISPR-Cas9 Improves Its Antitumor Effects as Cellular Immunotherapy for Human Colon Cancer.
Gao L; Yang L; Zhang S; Ge Z; Su M; Shi Y; Wang X; Huang C
J Interferon Cytokine Res; 2021 Dec; 41(12):450-460. PubMed ID: 34935484
[TBL] [Abstract][Full Text] [Related]
35. Shooting the messenger: RNA-targetting CRISPR-Cas systems.
Zhu Y; Klompe SE; Vlot M; van der Oost J; Staals RHJ
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29748239
[TBL] [Abstract][Full Text] [Related]
36. CRISPR: development of a technology and its applications.
Derry WB
FEBS J; 2021 Jan; 288(2):358-359. PubMed ID: 33300275
[TBL] [Abstract][Full Text] [Related]
37. Computational design of anti-CRISPR proteins with improved inhibition potency.
Mathony J; Harteveld Z; Schmelas C; Upmeier Zu Belzen J; Aschenbrenner S; Sun W; Hoffmann MD; Stengl C; Scheck A; Georgeon S; Rosset S; Wang Y; Grimm D; Eils R; Correia BE; Niopek D
Nat Chem Biol; 2020 Jul; 16(7):725-730. PubMed ID: 32284602
[TBL] [Abstract][Full Text] [Related]
38. CRISPR Guide RNA Design Guidelines for Efficient Genome Editing.
Schindele P; Wolter F; Puchta H
Methods Mol Biol; 2020; 2166():331-342. PubMed ID: 32710418
[TBL] [Abstract][Full Text] [Related]
39. Robust genome editing in adult vascular endothelium by nanoparticle delivery of CRISPR-Cas9 plasmid DNA.
Zhang X; Jin H; Huang X; Chaurasiya B; Dong D; Shanley TP; Zhao YY
Cell Rep; 2022 Jan; 38(1):110196. PubMed ID: 34986352
[TBL] [Abstract][Full Text] [Related]
40. A Compact, High-Accuracy Cas9 with a Dinucleotide PAM for In Vivo Genome Editing.
Edraki A; Mir A; Ibraheim R; Gainetdinov I; Yoon Y; Song CQ; Cao Y; Gallant J; Xue W; Rivera-Pérez JA; Sontheimer EJ
Mol Cell; 2019 Feb; 73(4):714-726.e4. PubMed ID: 30581144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
